Form 8-K - Current report:
SEC Accession No. 0001193125-21-326406
Filing Date
2021-11-12
Accepted
2021-11-10 20:17:40
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d244737d8k.htm   iXBRL 8-K 23286
2 EX-99.1 d244737dex991.htm EX-99.1 76300
6 GRAPHIC g244737g1111040928824.jpg GRAPHIC 3669
  Complete submission text file 0001193125-21-326406.txt   240434

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA glue-20211110.xsd EX-101.SCH 2889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE glue-20211110_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE glue-20211110_pre.xml EX-101.PRE 11858
7 EXTRACTED XBRL INSTANCE DOCUMENT d244737d8k_htm.xml XML 3478
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 211398584
SIC: 2836 Biological Products, (No Diagnostic Substances)